Aravive ( ) - 株価, ニュースと分析Nasdaq:ARAV

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ARAV 株式概要

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States.

会社概要

ARAV ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	3/6
配当金	0/6

報酬

リスク分析

過去5年間で収益は年間12.3%減少しました。

キャッシュランウェイが1年未満である

過去3か月間の株価の変動は非常に激しい

意味のある時価総額がありません ( $3M )

+1 さらなるリスク

Aravive, Inc. 競合他社

Trevena

NasdaqCM:TRVN

US$3.4m

Fresh2 Group

NasdaqCM:FRES

US$3.0m

AXIM Biotechnologies

OTCPK:AXIM

US$1.9m

AquaBounty Technologies

NasdaqCM:AQB

US$4.8m

価格と性能

の歴代最高値、変動、値下がりまとめAravive
過去の株価
現在の株価	US$0.04
52週高値	US$2.46
52週安値	US$0.04
ベータ	2.19
11ヶ月の変化	-67.58%
3ヶ月変化	-69.30%
1年変化	-97.63%
33年間の変化	-99.22%
5年間の変化	-99.06%
IPOからの変化	-99.98%

Recent updates

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

株主還元

	ARAV	US Biotechs	US 市場
7D	-17.3%	-2.8%	0.7%
1Y	-97.6%	19.3%	32.3%

業界別リターン: ARAV過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: ARAVは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is ARAV's price volatile compared to industry and market?
ARAV volatility
ARAV Average Weekly Movement	19.5%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

安定した株価: ARAVの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ARAVの weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2008	23	n/a	aravive.com

Aravive, Inc. 基礎のまとめ

Aravive の収益と売上を時価総額と比較するとどうか。
ARAV 基礎統計学
時価総額	US$2.95m
収益（TTM）	-US$39.85m
売上高(TTM)	US$6.99m

0.4x

P/Sレシオ

-0.1x

PER（株価収益率

ARAV は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ARAV 損益計算書（TTM）
収益	US$6.99m
売上原価	US$53.39m
売上総利益	-US$46.39m
その他の費用	-US$6.55m
収益	-US$39.85m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.54
グロス・マージン	-663.34%
純利益率	-569.73%
有利子負債／自己資本比率	0%

ARAV の長期的なパフォーマンスは？

過去の実績と比較を見る

ARAV 株式概要

報酬

リスク分析

Aravive, Inc. 競合他社

NasdaqCM:TRVN

US$3.4m

NasdaqCM:FRES

US$3.0m

OTCPK:AXIM

US$1.9m

NasdaqCM:AQB

US$4.8m

価格と性能

最新ニュース

Aravive Files Form 15

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc. Notifies Nasdaq of its Intention to File a Form 25 on or About January 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Recent updates

Aravive Files Form 15

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc. Notifies Nasdaq of its Intention to File a Form 25 on or About January 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Aravive, Inc., Annual General Meeting, Oct 02, 2023

Consensus revenue estimates decrease by 51%

Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Consensus revenue estimates increase by 95%

Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 35%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive, Inc. Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian

Aravive Inc. Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 44%

Price target decreased to US$9.80

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aravive, Inc. announced that it has received $41.559988 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC, and other investors

Consensus forecasts updated

Aravive, Inc. announced that it expects to receive $41.55547 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC

Consensus forecasts updated

Aravive Receives Third Development Milestone from 3D Medicines

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Consensus revenue estimates increase by 10%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Aravive Q2 GAAP EPS misses, revenue beats

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive appoints Robert Geller as CMO

Price target decreased to US$18.20

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Aravive, Inc. Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 25%

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

High number of new directors

Consensus forecasts updated

Price target decreased to US$19.75

Aravive, Inc. Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Aravive, Inc. Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

High number of new directors

Aravive, Inc. announced that it has received $10.000001 million in funding from Eshelman Ventures, LLC

Aravive, Inc. announced that it expects to receive $10.000001 million in funding from Eshelman Ventures, LLC

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive Inc Announces First Patient Dosed in Phase 1B/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Consensus revenue estimates increase to US$7.34m

Aravive, Inc.(NasdaqGS:ARAV) dropped from Russell Microcap Growth Index

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Consensus revenue estimates increase to US$4.10m

Aravive, Inc. Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive EPS beats by $0.01, misses on revenue

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer